NEWS
The Unsung Hero of the OBBBA: Permanent Expensing
The One Big Beautiful Bill (OBBB), signed into law on July 4, 2025, prevented a large, scheduled tax hike from hitting American households.
Alex Brill Interviewed by Biosimilars Review & Report
Following the release of the new MGA white paper “The Long-Term Effects of Medicare Price Negotiations on Drug Competition,” Alex Brill spoke with Stanton Mehr at Biosimilars Review & Report.
MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
This week, MGA released a new white paper by Alex Brill and Christy Robinson looking at the long-term effects of Medicare price negotiations on drug competition
The 340B Program’s Negative Impact on Pharmaceutical Innovation
As the Department of Health and Human Services considers changes to the federal 340B drug program, including switching mandatory drug manufacturer contributions from discounts to rebates, it is important for policymakers to recognize the myriad concerns with this program.
A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax Reform
On March 5, Speaker Ryan moderated a panel on tax policy with AEI’s Alex Brill and Kyle Pomerleau.
New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
Congress on the Brink of Disrupting the PBM Market
During much of 2024, the prevailing view in Washington was that some policies related to pharmacy benefit managers (PBMs) would be included in the end-of-year continuing resolution.
Raising the Salt Cap Would Increase Tax Complexity
The individual provisions of the Tax Cuts and Jobs Act (TCJA) are set to expire at the end of 2025. The Republican-controlled Congress intends to extend these tax cuts but some Republican lawmakers are demanding changes.
Economics of “Delinking” Are Still Not Good
Delinking would lead to higher costs for patients and taxpayers and put more money in the pockets of brand drug manufacturers.
The Child Tax Credit: Tradeoffs and Preferences
There has been a flurry of discussion in Washington recently about potential reforms to the child tax credit (CTC).
Oregon’s Measure 118: The Turnover Tax Is the Worst
Next week, Oregon voters will weigh in on a tax-related ballot measure with concerning repercussions.
Dueling Child Tax Credit Proposals: Harris vs. Vance
JD Vance and Kamala Harris have at least one thing in common: proposals to expand the child tax credit (CTC). Currently, the CTC offers households up to $2,000 per child under the age of 17.
Trump Proposes Bringing Back the Deduction for Auto Loan Interest
During a recent speech at the Detroit Economic Club, former President Donald Trump proposed partially renewing a tax policy in effect prior to the Tax Reform Act of 1986 that allowed taxpayers to fully deduct interest expense on auto loans.
Overtime Income Tax Break: Not Illogical, Just Costly and Complicated
Last month, former President Donald Trump declared, “If you’re an overtime worker, when you’re past 40 hours a week . . . your overtime hours will be tax-free.”
Presidential Candidates’ Dueling Child Credit Expansions Explained
The Trump-Vance and Harris-Walz presidential campaigns have each recently proposed large expansions to the child tax credit (CTC). Both proposals might be intended to appeal to similar voters, but they vary significantly regarding budgetary cost, distribution of benefits, and effect on work incentives.
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
- A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax Reform
- New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
- Congress on the Brink of Disrupting the PBM Market
- Raising the Salt Cap Would Increase Tax Complexity
- Economics of “Delinking” Are Still Not Good
- The Child Tax Credit: Tradeoffs and Preferences
